[Retroperitoneal lymph node dissection for patients with advanced testicular tumor]

Area of Science:

• Oncology
• Urology
• Surgical Oncology

Background:

• Advanced testicular tumors often require multimodal treatment.
• Retroperitoneal lymph node dissection (RPLND) is a key surgical intervention.
• The optimal timing and indication for RPLND in conjunction with chemotherapy remain areas of investigation.

Purpose of the Study:

• To evaluate the indications for retroperitoneal lymph node dissection (RPLND) in patients with advanced testicular tumors.
• To determine the impact of the sequence of RPLND and chemotherapy on therapeutic outcomes.
• To establish criteria for performing RPLND in non-seminomatous germ cell tumors (NSGCT) and seminoma.

Main Methods:

• Retrospective analysis of 30 patients with advanced testicular tumors undergoing RPLND.
• Comparison of therapeutic effects based on the sequence of RPLND and primary chemotherapy.
• Assessment of residual retroperitoneal tumors after chemotherapy or irradiation therapy.

Main Results:

• For Stage IIA NSGCT, the sequence of RPLND and chemotherapy showed no significant difference in therapeutic effect.
• Primary chemotherapy prior to RPLND is recommended for Stage IIA NSGCT to minimize tumor cell dissemination.
• In advanced NSGCT (beyond Stage IIB), RPLND is often necessary for residual retroperitoneal tumors post-chemotherapy.
• For seminoma, RPLND may not be necessary if residual tumors are <3 cm or show >80% reduction post-therapy.

Conclusions:

• The timing of RPLND relative to chemotherapy does not alter outcomes for Stage IIA NSGCT, but pre-operative chemotherapy is preferred.
• RPLND remains a critical component for managing residual retroperitoneal disease in advanced NSGCT.
• Specific criteria regarding residual tumor size and response to initial therapy can guide the necessity of RPLND in seminoma patients.